Markets:

Overview

News

Currencies

International

Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

51.24 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...

Via MarketMinute

3 Low-Volatility Stocks We’re Skeptical Of

December 31, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

3 of Wall Street’s Favorite Stocks That Concern Us

December 22, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

A Preview Of Supernus Pharmaceuticals's Earnings ↗

November 03, 2025

Via Benzinga

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗

December 19, 2025

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.

Via Stocktwits

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back ↗

December 15, 2025

The sale hints at profit-taking in a stock that’s executing operationally but facing tougher questions about durability and valuation.

Via The Motley Fool

Topics Regulatory Compliance

1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down

December 14, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

3 Stocks Under $50 That Concern Us

December 11, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

3 Unprofitable Stocks We Find Risky

December 03, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

December 03, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds

November 23, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 14.4% over...

Via StockStory

Topics Stocks

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 21, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

November 21, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and...

Via StockStory

Topics Artificial Intelligence Intellectual Property

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Via The Motley Fool

3 Russell 2000 Stocks Walking a Fine Line

November 13, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

November 12, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call

November 11, 2025

Supernus Pharmaceuticals reported Q3 results that were above Wall Street’s revenue and profit expectations, but the market reacted negatively, reflecting concerns over execution challenges and forward...

Via StockStory

Topics Earnings

Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today

November 05, 2025

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 16.8% in the morning session after the company's third-quarter 2025 earnings report, as a weak full-year forecast...

Via StockStory

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs

November 05, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the...

Via StockStory

Topics Supply Chain

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3

November 04, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $192.1 million. On the...

Via StockStory

Supernus Announces Third Quarter 2025 Financial Results

November 04, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2

November 03, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings

November 02, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

3 Cash-Producing Stocks That Fall Short

October 30, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate ↗

October 28, 2025

Supernus Pharmaceuticals (SUPN) offers affordable growth with strong EPS, solid financials, and a low P/E ratio, making it a compelling investment opportunity.

Via Chartmill

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗

October 23, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.